Back to search results

DBS Programming for Parkinson's Disease

This study is looking at new ways to program Deep Brain Stimulation (DBS) devices for people with Parkinson's disease (PD). Currently, doctors manually choose the best settings for your DBS device. This study will compare that standard method with two new approaches that use signals from your brain (called local field potentials or LFPs) to find the best settings. One new approach focuses on 'beta power' and the other uses a broader range of brain signals. The goal is to see if these new methods can improve your motor symptoms, which will be measured using a standard Parkinson's disease rating scale (UPDRS). You may be able to join if you have been diagnosed with PD, have a Medtronic Percept DBS device, are between 21 and 89 years old, and are willing to participate during your initial programming session. The study plans to enroll up to 30 patients.

Study design
This is an interventional study that plans to enroll up to 30 participants. It will compare three different ways of programming DBS devices.
What's involved
You would participate at the time of your initial DBS programming session. The study will assess your motor symptoms from enrollment to the end of the study, which is 1 month.
Compensation
Not stated in the trial record.
Follow-up
Your motor symptoms will be assessed for 1 month after enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07348705

Electrophysiology-based DBS Programming for PD

Recruiting
NAAges 21–89InterventionalTreatment
University of Florida
~30 participants
Updated 2026-03-30 on ClinicalTrials.gov
What's tested:Clinician-based DBS programmingMaximum Beta power-based DBS programmingBroad-band electrophysiology-based DBS programming

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assessment of motor symptoms using the Unified Parkinson's Disease Rating Scale (UPDRS)
Measured over From enrollment to end of study (1 month)

Conditions

Parkinson's Disease (PD)

Explore related trials

Parkinson Disease

NCT07348705

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Norman Fixel Institute for Neurological Diseases

    Gainesville, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Joshua Wong, MD · PRINCIPAL_INVESTIGATOR · University of Florida

Who to contact

Joshua Wong, MD
[email protected]
352-294-5400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients with a diagnosis of idiopathic PD fulfilling the Movement Disorder Society Clinical Diagnostic Criteria for PD
DBS implantation with the Percept DBS device (Medtronic, USA) for the treatment of motor symptoms
Ability to give informed consent for the study
Willingness to do this study at the time of the initial programming session
Age 21 to 89 years old

Exclusion

Inability to comply with the study protocol
Atypical Parkinsonism
Any personality or mood symptoms that study personnel believe will interfere with the study requirements

What this trial measures

  • Assessment of motor symptoms using the Unified Parkinson's Disease Rating Scale (UPDRS)From enrollment to end of study (1 month)

    The UPDRS (Unified Parkinson's Disease Rating Scale) Motor Scale (Part III) is a clinician-rated tool assessing motor functions like tremor, rigidity, bradykinesia, and gait in Parkinson's disease (PD), using a 0-4 scale for each item, with higher scores indicating greater impairment, helping track disease progression and treatment response.